Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Semilente®MC in Children, Adolescents and Young Adults With Type 1 Diabetes on Basal-Bolus Regimen.

This trial is conducted in Europe.

A 32-week efficacy and safety comparison of insulin detemir and insulin semilente MC in children between 6 and 21 years with type 1 diabetes.

Inclusion Criteria:

• Type 1 diabetes
• Current intensified insulin treatment
• Injection of insulin Semilente®MC at bedtime for at least 6 weeks
• BMI maximum 32 kg/m^2
• HbA1c > 5.5 % and < 12.0 %

Exclusion Criteria:

• Current treatment with premixed insulin(s)
• Impaired hepatic or renal function
• Recurrent major hypoglycaemia